Evaluation of Biomarkers for Alzheimer Disease

Biochemical changes associated with the pathophysiology of Alzheimer disease (AD) are being evaluated to aid in the diagnosis of AD. This includes the potential use of biomarkers, such as amyloid beta peptide 1-42 and total or phosphorylated tau protein, in cerebrospinal fluid (CSF) and urine. Additionally, the potential correlation between CSF biomarkers and positron emission tomography (PET) amyloid scans may assist in selecting appropriate patients for the initiation or discontinuation of amyloid beta plaque targeted therapy.